Skip to main
INVA

Innoviva (INVA) Stock Forecast & Price Target

Innoviva (INVA) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 20%

Bulls say

Innoviva is poised for success with a diverse portfolio of assets and promising products in the pipeline, a strong financial position, and strategic investments. Their recent financial results have surpassed expectations, and their hospital-based products are showing strong growth potential. While there may be industry risks, BTIG, LLC values Innoviva favorably using an NPV SOTP analysis, making them a compelling investment opportunity.

Bears say

Innoviva is highly dependent on its Xacduro product, which has shown strong launch ramp and exceeded management's expectations. However, the company's over-reliance on a single product makes it vulnerable to potential resistance and increasing competition in the hospital setting, which could negatively impact its revenue and financial performance. As such, the company's overall financial outlook is uncertain and may have a negative impact on its stock.

Innoviva (INVA) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 20% predict a Strong Sell.

This aggregate rating is based on analysts' research of Innoviva and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Innoviva (INVA) Forecast

Analysts have given Innoviva (INVA) a Buy based on their latest research and market trends.

According to 5 analysts, Innoviva (INVA) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $34.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $34.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Innoviva (INVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.